Chalabi, Myriam

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 1,417

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 1,135

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine

Colorectal Cancer Treatments and StudiesCancer Cells and Metastasis

Cited by 813

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

de Vries, N. L., van de Haar, J., Veninga, V., Chalabi, M., Ijsselsteijn, M. E., van der Ploeg, M., van den Bulk, J., Ruano, D., van den Berg, J. G., Haanen, J. B., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 311

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 294

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

André, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., Schenker, M., de la Fouchardiere, C., Limon, M. L., Yoshino, T., et al. (2024) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 286

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial

André, T., Elez, E., Lenz, H.-J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., Garcia-Carbonero, R., Tougeron, D., Mendez, G. A., Schenker, M., et al. (2025) · The Lancet

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 256